Investors are questioning whether the AI infrastructure buildout is overheated, and Caterpillar's downgrade shows that even industrial companies riding the data-center wave are now vulnerable to a sentiment shift. Boston Scientific represents the opposite

Verdict: compelling rotation thesis, but wait for momentum confirmation

The rotation thesis is intellectually sound: Boston Scientific delivered 19.9% revenue growth and 55.2% diluted EPS growth for FY 2025, with an 18.0% operating margin in the 91st percentile of health-care peers, while Caterpillar's EPS declined 14.7% and its July 29 CNBC downgrade validates the idea's core premise. However, the trade is not yet actionable — both momentum triggers (MACD at -1.79, Williams %R at -33.1) remain far from their entry thresholds, BSX sits just $0.40 above the 20-day EMA that gates the setup, and the 27.4% backtested return rests on only 2 trades with a 50% win rate, meaning the favorable return-to-drawdown ratio is statistically thin. CAT's 41.7% ROE and $8.9B in free cash flow also suggest the short leg's downside may be self-limiting if data-center spending cools without collapsing. No robust parameter setup was established, as the sensitivity analysis exceeded its time budget without producing a recommendation. **Conviction breakdown:** - **Thesis support (62/100):** The fundamental divergence between BSX's accelerating growth and CAT's deceleration is genuine and well-catalyzed by current news. - **Trade readiness (25/100):** BSX needs a 1.79-point MACD improvement and a 13-point Williams %R move; CAT's triggers are deeply out of range, making entry imminent on neither leg. - **Risk quality (40/100):** The 2:1 reward-to-risk framework is sound, but exits were filled on trigger-timeframe bars (not intrabar), and BSX's fat left-tail risk (skewness of -3.05, kurtosis of 26.9) could blow through the 2.6% stop in a gap-down. - **Backtest evidence (28/100):** Two trades with a 50% win rate across a 60-month window is insufficient to distinguish skill from luck, even with a favorable 27.4% return and 13.0% max drawdown. - **Fundamentals trend (75/100):** BSX's revenue, margins, and free cash flow are all trending favorably and rank in the 91st–99th percentile of peers, though its 6.6% ROA and 0.46 debt-to-equity introduce friction.

Trade now

Boston Scientific (BSX) closed at $45.52 — above its 20-day EMA ($45.12) and below its 50-day SMA ($51.69), satisfying two of the strategy's four entry conditions. The structural setup is intact: price is holding its short-term floor while remaining in a longer-term pullback zone. However, two momentum triggers are not yet live. The MACD histogram sits at roughly -1.79 and needs to cross above zero — it is still meaningfully negative. Separately, Williams %R (14) reads about -33 and must rise above -20 to confirm bullish momentum. For Caterpillar (CAT), the picture is weaker. At $782.71, CAT is trading well below its 20-day EMA ($877.04) and its 50-day SMA ($919.59), with an RSI of 14.7 and Williams %R at -95.0 — all three momentum conditions are deep in oversold territory. The strategy is not close to triggering a long on CAT today. Once entered, the strategy's hard stop is a 2.6% loss from fill (exit rule: unrealized PnL at or below -2.6%), and the hard take-profit is a 5.1% gain. That yields an effective reward-to-risk ratio of roughly 2:1. The backtest produced a 27.4% return over the evaluation window with a 50% win rate across two trades and a worst-pair max drawdown of 13.0%. No parameter-sensitivity recommendation was established, so no adjusted setup is being applied. "Wait" means do nothing until BSX simultaneously prints a MACD histogram crossover above zero and a Williams %R reading above -20 while holding above its 20-day EMA and below its 50-day SMA. That convergence has not happened. Do not leg in early on a partial signal.

Why the rotation into real growth holds up

The thesis hinges on Boston Scientific offering investors a refuge from AI-infrastructure jitters, and the fundamentals back that argument. BSX posted revenue of $20.1B for FY 2025, growing 19.9% year-over-year, while diluted EPS grew 55.2% over the same period. Per the Yahoo Finance article published on July 29, 2026, the company beat second-quarter expectations and raised its full-year outlook, giving the…

Scores

• Conviction score breakdown: 46
• Thesis support: 62
• Trade readiness: 25
• Risk quality: 40
• Backtest evidence: 28
• Fundamentals trend: 75

Watch items

• BSX — MACD (12,26,9) histogram
• BSX — Williams %R (14)
• BSX — Price vs 20-day EMA
• BSX — Price vs nearest resistance
• CAT — Price vs 20-day EMA
• CAT — Williams %R (14)
• BSX — Price above EMA (20)
• BSX — MACD (12,26,9) crossed above 0
• BSX — Williams %R (14) above -20
• BSX — Price below SMA (50)